SCHEMBL17211652

SCHEMBL17211652

CCOC(=O)/C=C/c1cc(NS(=O)(=O)c2cccs2)c2c(c1C)OCO2

nearest known ligand 0.85

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CNKSR1 Q969H4 12/20 0.85
AKT1 P31749 2/20 0.85
MEN1 O00255 2/20 0.44
MAPT P10636 2/20 0.44
KMT2A Q03164 2/20 0.44
NPSR1 Q6W5P4 1/20 0.44
HIF1A Q16665 1/20 0.44
ALDH1A1 P00352 3/20 0.42
PLK1 P53350 1/20 0.42
PKM P14618 1/20 0.40
HSD17B10 Q99714 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40
TSHR P16473 1/20 0.40
CYP2C19 P33261 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15811518 0.92 CNKSR1 (1.00) CNKSR1AKT1MEN1MAPTKMT2A
SCHEMBL15811504 0.90 CNKSR1 (0.81) CNKSR1AKT1MEN1MAPTKMT2A
SCHEMBL17211659 0.88 CNKSR1 (0.80) CNKSR1AKT1MEN1MAPTKMT2A
SCHEMBL18160885 0.85 CNKSR1 (0.75) CNKSR1AKT1MEN1MAPTKMT2A
SCHEMBL18160894 0.81 CNKSR1 (0.80) CNKSR1AKT1MEN1MAPTKMT2A
SCHEMBL18148025 0.81 CNKSR1 (1.00) CNKSR1AKT1MEN1MAPTKMT2A
SCHEMBL17211656 0.81 CNKSR1 (1.00) CNKSR1AKT1MEN1MAPTKMT2A
SCHEMBL17211658 0.80 CNKSR1 (0.60) CNKSR1AKT1MEN1MAPTKMT2A
SCHEMBL17211669 0.79 CNKSR1 (0.78) CNKSR1AKT1MEN1MAPTKMT2A
SCHEMBL17211718 0.79 CNKSR1 (0.64) CNKSR1AKT1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160304533-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR INHIBITING CNKSR1 PHUSIS THERAPEUTICS, INC. (US) 2016-10-20 US disclosed
US-9340532-B2 Methods and compositions for inhibiting CNKSR1 PHUSIS THERAPEUTICS, INC. (US) 2016-05-17 US disclosed
US-20150307482-A1 METHODS AND COMPOSITIONS FOR INHIBITING CNKSR1 PHUSIS THERAPEUTICS, INC. (US) 2015-10-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150307482-A1 METHODS AND COMPOSITIONS FOR INHIBITING CNKSR1 CNKSR1, CAMKK1, CAMKK2 CNKSR1 1/4885AKT1 936/4885MEN1 2772/4885
US-20160304533-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR INHIBITING CNKSR1 CNKSR1, CAMKK1, CNR1 CNKSR1 1/4885AKT1 780/4885MEN1 2360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.